Article Details
Retrieved on: 2022-06-04 14:08:50
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
WILMINGTON, Del., June 04, 2022--Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) maintained a ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here